Osteochondral Tissue Chip Derived From iPSCs: Modeling OA Pathologies and Testing Drugs
Osteoarthritis (OA) is a chronic disease mainly characterized by degenerative changes in cartilage, but other joint elements such as bone are also affected. To date, there are no disease-modifying OA drugs (DMOADs), owing in part to a deficiency of current models in simulating OA pathologies and eti...
Main Authors: | Zixuan Lin, Zhong Li, Eileen N. Li, Xinyu Li, Colin J. Del Duke, He Shen, Tingjun Hao, Benjamen O'Donnell, Bruce A. Bunnell, Stuart B. Goodman, Peter G. Alexander, Rocky S. Tuan, Hang Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Bioengineering and Biotechnology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fbioe.2019.00411/full |
Similar Items
-
Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs
by: Yi Yang, et al.
Published: (2018-01-01) -
The safety and effectiveness of genetically corrected iPSCs derived from β-thalassaemia patients in nonmyeloablative β-thalassaemic mice
by: Yexing Xian, et al.
Published: (2020-07-01) -
Targeted gene correction and functional recovery in achondroplasia patient-derived iPSCs
by: Huan Zou, et al.
Published: (2021-08-01) -
iPSCs are safe!
by: Hualong Yan, et al.
Published: (2017-05-01) -
iPSCs: A Preclinical Drug Research Tool for Neurological Disorders
by: Gabriele Bonaventura, et al.
Published: (2021-04-01)